Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA).
Qinglei GaoJian Qing ZhuWeidong ZhaoYi HuangRuifang AnHong ZhengPengpeng QuLi WangQi ZhouDanbo WangGe LouJing WangKe WangJohn LowBeihua KongAbdul Malik RozitaLim Chun SenRutie YinXing XieJihong LiuWei SunJingya SuChunyi ZhangRongyu ZangDing MaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Olaparib maintenance therapy was highly effective and well tolerated in Asian patients with PSR ovarian cancer, regardless of BRCA status. This study highlights the promising efficacy of olaparib in this Asian population. See related commentary by Nicum and Blagden, p. 2201.